Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Pharmaceutical intermediates >  Heterocyclic compound >  Pyrimidines >  Bromopyrimidine >  3-broMo-5,7-dichloropyrazolo(1,5-a)pyriMidine

3-broMo-5,7-dichloropyrazolo(1,5-a)pyriMidine

Basic information Safety Supplier Related

3-broMo-5,7-dichloropyrazolo(1,5-a)pyriMidine Basic information

Product Name:
3-broMo-5,7-dichloropyrazolo(1,5-a)pyriMidine
Synonyms:
  • Pyrazolo[1,5-a]pyrimidine, 3-bromo-5,7-dichloro-
  • 3-Bromo-5,7-dichloropyrazolo[1,5-a]pyrimidine
  • 3- bromide -5, 7- two chloro pyrazole, [1, 5-A] pyrimidine
  • 3-broMo-5,7-dichloropyrazolo(1,5-a)pyriMidine ISO 9001:2015 REACH
CAS:
114040-06-1
MF:
C6H2BrCl2N3
MW:
266.91
Product Categories:
  • API intermediates
Mol File:
114040-06-1.mol
More
Less

3-broMo-5,7-dichloropyrazolo(1,5-a)pyriMidine Chemical Properties

Melting point:
73-75 °C
Density 
2.16
storage temp. 
under inert gas (nitrogen or Argon) at 2-8°C
pka
-3.17±0.40(Predicted)
Appearance
Yellow to brown Solid
InChI
InChI=1S/C6H2BrCl2N3/c7-3-2-10-12-5(9)1-4(8)11-6(3)12/h1-2H
InChIKey
CJIKMWXLGRVJMI-UHFFFAOYSA-N
SMILES
C12=C(Br)C=NN1C(Cl)=CC(Cl)=N2
More
Less

3-broMo-5,7-dichloropyrazolo(1,5-a)pyriMidine Usage And Synthesis

Uses

3-Bromo-5,7-dichloro-pyrazolo[1,5-a]pyrimidine is an intermediate used in the synthesis of inhibitors of mitogen-activated protein kinase-activated protein kinase 2 as an antiinflammatory target.

Synthesis

57489-77-7

114040-06-1

General procedure for the synthesis of 3-bromo-5,7-dichloropyrazolo[1,5-a]pyrimidines from 5,7-dichloropyrazolo[1,5-a]pyrimidines: To a solution of 5,7-dichloropyrazolo[1,5-a]pyrimidines (1 g, 5.32 mmol) in acetonitrile (20 mL) was added N-bromosuccinimide (1.04 g, 5.85 mmol) and ammonium ceric nitrate (0.029 g, 0.053 mmol). The reaction mixture was heated to reflux for 1 hour. After completion of the reaction, the reaction mixture was washed sequentially with 10% aqueous sodium bisulfite (30 mL) and brine (20 mL). The organic phase was dried with magnesium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with 20% ether/hexane as eluent to afford 3-bromo-5,7-dichloropyrazolo[1,5-a]pyrimidine as a yellow solid (1.33 g, 92% yield). δH (400 MHz; d4-CDCl3) 8.22 (1H, s), 7.04 (1H, s).

References

[1] Patent: WO2004/87707, 2004, A1. Location in patent: Page 33; 34
[2] Patent: WO2014/75168, 2014, A1. Location in patent: Page/Page column 53
[3] Patent: WO2015/70349, 2015, A1. Location in patent: Page/Page column 22; 23
[4] ACS Medicinal Chemistry Letters, 2016, vol. 7, # 7, p. 671 - 675
[5] Journal of Medicinal Chemistry, 2012, vol. 55, # 15, p. 6700 - 6715

3-broMo-5,7-dichloropyrazolo(1,5-a)pyriMidineSupplier

Chiba Pharmaceutical Science and technology Co, Ltd. Gold
Tel
0531-81313138 13066006660
Email
chibapharm@foxmail.com
J & K SCIENTIFIC LTD.
Tel
18210857532; 18210857532
Email
jkinfo@jkchemical.com
PharmaBlock Sciences (Nanjing),Inc.
Tel
025-86918202 4000255188
Email
sales@pharmablock.com
Changzhou Huanling Chemical Co., Ltd.
Tel
0519-89803565 13776850645
Email
info4@huanlingchem.com
Adamas Reagent, Ltd.
Tel
400-6009262 16621234537
Email
chenyj@titansci.com